MANEUVER study results presented at ASCO 2025, Sarcoma Oral Session.
Pimicotinib was able to induce 54% RECIST and 61.9% volumetric responses in patients with symptomatic TGCT.
Honoured to be part of this study #ASCO2025#TGCT#sarcoma
@montieljf@BrotoJavier@GrupoGeis@Hospital_FJD@SarcomasAEC Primera Jornada para pacientes de sarcoma de la Fundación Jimenez Diaz! Gracias a todos los pacientes por la participación entusiasta y a la Fundación Maripaz Jimenez Casado y asociaciones de pacientes de sarcoma por promover esta jornada en toda España!#sarcoma
A giant among us has departed. Prof. Chris D.M.Fletcher passed away peacefully yesterday in Boston. He impacted our entire field, and he will be missed greatly. It was an honor to work with him and to learn from him.
Thank you Dr Sandra Strauss for you great presentation on the results of dediff Chondrosarcoma cohort of IMMUNOSARC study with the combination of sunitinib plus nivolumab. Great hints of activity of immunotherapy in this orphan and aggressive disease.
@GrupoGeis#ASCO24#immuno
New data on Chemo-Immuno in first line of advanced STS. Impressive results from the doxo-ifo-sintilimab, that mirror our results presented last year in the Immunosarc LMS cohort.
#ASCO24#sarcoma#Immunotherapy